Navigation Links
Few Women at High Risk for Breast Cancer Take Tamoxifen
Date:2/11/2010

Study finds less than 1% use it as preventative; experts say drug has gotten 'bad rap'

THURSDAY, Feb. 11 (HealthDay News) -- Only a tiny fraction of women at high risk of developing breast cancer take tamoxifen to prevent the disease.

This news comes despite the fact that experts have known since 1998 that tamoxifen can cut the risk of developing breast cancer by almost 50 percent.

"This is not a surprise to me," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La., which was one of the sites enrolling women for the trial that led to the approval of using tamoxifen for breast cancer prevention.

"The drug is actually a very fine drug for breast cancer prevention, but it has gotten a bad rap," Brooks continued. "I don't think we have changed the paradigm of the fact that we can predict which women are at increased risk for this disease and we can do something to lower their risk short of prophylactic mastectomy, but I don't think the medical profession has been able to communicate well enough to women so that they can understand that taking medicine can lower their risk of cancer."

V. Craig Jordan, scientific director of the Lombardi Comprehensive Cancer Center at Georgetown University, who is considered the "father" of tamoxifen, agreed: "There has been so much negative publicity about tamoxifen. No good information is being provided. That doesn't help."

While people are relatively comfortable with the notion that blood pressure and cholesterol drugs can lower the risk of heart problems in people who feel perfectly healthy, this is still an alien concept in the cancer world, Brooks said.

In addition to being used to treat breast tumors, tamoxifen (Nolvadex) is approved to prevent breast cancer recurrences and to prevent tumors in women who have not yet been diagnosed with the disease.

These authors looked at data from 2000 and 2005 from a large national survey (including about 10,000 women for each year) to estimate how many women were using tamoxifen for primary prevention of breast cancer.

In 2000, only about 0.2 percent of U.S. women aged 40 to 79 took tamoxifen to prevent breast cancer. In 2005, the prevalence was even lower -- only 0.08 percent.

The data did not say specifically how many of the women taking tamoxifen were at high risk for breast tumors, said Andrew N. Freedman, senior author of the paper appearing in the February issue of Cancer Epidemiology, Biomarkers & Prevention, but "we probably could assume they were high-risk."

The authors could only speculate on why the numbers were so low.

"It may be that patients and their physicians do not think the benefits outweigh the risks. It could be that physicians are not getting education about use of the drug. It could be concerns about side effects or physicians reluctant to prescribe," said Freedman, who is chief of the clinical and translational epidemiology branch of the division of cancer control and population sciences at the U.S. National Cancer Institute.

One recent study found that worries about side effects are a major reason why high-risk women are unwilling to take tamoxifen.

Tamoxifen's side effects include hot flashes, endometrial cancer and blood clots. A newer agent, raloxifene (Evista), a sister drug to tamoxifen, might be an alternative for women concerned about the risk of endometrial cancer.

However, tamoxifen works for both invasive and noninvasive breast cancer while raloxifene works only for the former, Brooks said.

Also tamoxifen, said Jordan, "is the only game in town for premenopausal women."

In the end, though, the decision lies with each individual woman.

"I think that the use of tamoxifen for chemoprevention is something that is a very personal choice between the physician and patient, and depends on many, many factors," Freedman said.

More information

The U.S. National Cancer Institute has more on tamoxifen.



SOURCES: Andrew N. Freedman, Ph.D., chief, Clinical and Translational Epidemiology Branch, Division of Cancer Control and Population Sciences, U.S. National Cancer Institute, Bethesda, Md.; V. Craig Jordan, Ph.D., D.Sc., scientific director, Georgetown University Lombardi Comprehensive Cancer Center, Washington, D.C.; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; February 2010, Cancer Epidemiology, Biomarkers & Prevention


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Womens Dermatologic Society Marks 35th Anniversary with Release of Unprecedented Book of Wisdom and Inspiration
2. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
3. Cyndi Lauper, Lady Gaga Put Spotlight on Women and HIV
4. Womens Heart Disease Awareness Still Lacking
5. Diabetes drug ups risk for bone fractures in older women
6. Women More Likely to Fail Treatment for Atrial Fibrillation
7. LifestyleMom.com and the LifestyleMom Radio Cafe Aim to Help Women Create a Family Life and "Me Life" That They Truly Love
8. Company Invites Women to STOP PMS - Take the 10-Minute Challenge
9. Women with gout at greater risk of heart attack than men
10. Study finds higher risk of stillbirth in women with fibroids
11. Women Riders to Rev for a Cure at Daytona Bike Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... First Choice ... celebrating the one year anniversary of its Houston-Fallbrook facility. , “We are ... Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It has been a ...
(Date:9/22/2017)... ... ... “Letters From Home”: a moving compilation of letters that remind readers of the ... is the creation of published author, John Allred, a passionate leader of ministry to ... who has traveled and ministered on four continents. , “It is my hope and ...
(Date:9/21/2017)... , ... September 21, 2017 , ... With ProSlideshow Portrait ... and easy to do. Users can select from up to two layers of subject ... click of a mouse all within Final Cut Pro X. , With ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... learn with Infinity Behavioral Health Services for professionals in the addiction treatment industry ... Payer Audit . , Insurance companies and state and federal governments are ...
(Date:9/21/2017)... ... September 21, 2017 , ... Bill Howe Plumbing’s mission is to create an ... to the community. For over 37 years, they have operated with their mission at ... in San Diego. They were chosen as the Best San Diego plumber in ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... -- Eli Lilly and Company (NYSE: LLY ... galcanezumab and lasmiditan, two investigational treatments for migraine, at ... taking place Sept. 7-10 in Vancouver ... data from an open-label study evaluating the safety and ... 240 mg) for the prevention of migraine. Galcanezumab is ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
Breaking Medicine Technology: